Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00806572 · ClinicalTrials.gov registry record · Phase 2
Treatment With hOKT3gamma1(Ala-Ala) in T1DM
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00806572 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 10 participants.
The verdict
NCT00806572, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a phase II study to examine the clinical and immunological effects of humanized FcR non-binding anti-CD3 mAb in participants with Type 1 diabetes mellitus (T1DM), and to develop this therapy to prevent the immune destruction leading to β cell loss.
Interventions
- DRUG hOKT3gamma1(Ala-Ala)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2002-05 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00806572
The ClinicalTrials.gov registry entry for NCT00806572 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hOKT3gamma1(Ala-Ala) is the first listed.
NCT00806572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00806572 about?
NCT00806572 is a clinical study titled "Treatment With hOKT3gamma1(Ala-Ala) in T1DM". This is a phase II study to examine the clinical and immunological effects of humanized FcR non-binding anti-CD3 mAb in participants with Type 1 diabetes mellitus (T1DM), and to develop this therapy to prevent the immune destruction leading to β cell loss.
What is the current status of trial NCT00806572?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2002-05. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00806572?
The interventions under investigation include: hOKT3gamma1(Ala-Ala) (DRUG).
Who is sponsoring clinical trial NCT00806572?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.